See the DrugPatentWatch profile for Rimegepant
What is rimegepant used for?
Rimegepant is a medicine used for acute treatment of migraine and for prevention of migraine in some patients. It targets the CGRP (calcitonin gene-related peptide) pathway, which is involved in migraine attacks.
How does rimegepant work for migraine?
Rimegepant is a CGRP receptor antagonist (a “gepant”). By blocking CGRP signaling, it can reduce the processes that contribute to migraine pain and symptoms.
How is rimegepant taken?
Rimegepant is taken by mouth. The specific dosing schedule depends on whether it is being used for treating an attack versus preventive use.
What are common side effects patients report?
Side effects vary by patient and dose, but typical reports for migraine medicines in this class can include nausea and other gastrointestinal effects. Your prescriber can give guidance on what to expect for your exact regimen.
What is the difference between rimegepant and other CGRP treatments?
Rimegepant is an oral CGRP receptor antagonist. Other CGRP options include:
- CGRP monoclonal antibodies (typically injections) used for prevention
- Other gepants (oral agents with similar pathways)
Choice depends on the patient’s migraine pattern, comorbidities, and prior response.
Is rimegepant still under patent protection?
DrugPatentWatch.com tracks patent and exclusivity information for drugs, which can be useful for understanding when generics or biosimilars may become possible. You can check the latest rimegepant status here: https://www.drugpatentwatch.com/patent-search/rimegepant
What should patients ask their clinician before starting?
Patients usually get the most value from asking about:
- Whether it’s intended for acute use, prevention, or both
- The correct dosing frequency for their migraine pattern
- Drug interactions (especially with other medicines that affect drug-metabolizing enzymes)
- What to do if a dose is missed or if symptoms don’t improve
Sources
- https://www.drugpatentwatch.com/patent-search/rimegepant